172@29@17@241!~!172@29@0@53!~!|news|business|granules-india-gets-usfda-nod-for-sleep-aid-drug-5883921.html!~!news|moneycontrol|com!~!|controller|infinite_scroll_article.php!~!is_mobile=false
Moneycontrol
Watch experts decode 'The rise of ESG investing' on October 29 at 4pm. Register Now!
you are here: HomeNewsBusiness
Last Updated : Sep 25, 2020 12:51 PM IST | Source: PTI

Granules India gets USFDA nod for sleep aid drug

The US Food and Drug Administration (USFDA) has approved the abbreviated new drug application (ANDA) for Naproxen Sodium and Diphenhydramine Hydrochloride tablets, 220 mg/25 mg (OTC), Granules said in a BSE filing.

PTI
Representative image
Representative image
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Granules India on Friday said it has received the US health regulator's approval for Naproxen Sodium and Diphenhydramine Hydrochloride tablets, used for relief in occasional sleeplessness associated with minor aches and pains.

The approved product is the generic equivalent of Aleve PM tablets of Bayer HealthCare LLC.

The US Food and Drug Administration (USFDA) has approved the abbreviated new drug application (ANDA) for Naproxen Sodium and Diphenhydramine Hydrochloride tablets, 220 mg/25 mg (OTC), Granules said in a BSE filing.

Close

Granules now has a total of 31 ANDA approvals from the USFDA (29 Final approvals and 2 tentative approvals).

Shares of Granules India were trading 3.33 percent higher at Rs 372.60 apiece on BSE.
First Published on Sep 25, 2020 12:52 pm
Sections